Cod-Atorvastatin acts by competitively inhibiting HMG-CoA reductase, the first and key rate limiting enzyme of the cholesterol biosynthetic pathway. It mimics the natural substrate molecule, HMG-CoA, and compete for binding to the HMGCR enzyme